ABT vs MDT
ABT and MDT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABTABBOTT LABORATORIES | MDTMedtronic plc |
|---|---|---|
| Market cap | $192.30B | $116.07B |
| P/E (TTM) | 30.9 | 24.3 |
| P/B | 3.69 | 2.35 |
| P/S | 4.3x | 3.2x |
| Dividend yield | 2.14% | 3.14% |
| Revenue | $45.13B(TTM) | $36.36B(TTM) |
| Revenue growth (YoY) | 5.7% | 8.4% |
| Net income | $6.28B(TTM) | $4.8K(TTM) |
| Earnings growth (YoY) | -51.3% | 3.0% |
| EPS, diluted | $3.57(TTM) | $3.73(TTM) |
| EBIT margin | 18.2% | 17.8% |
| ROE | 12.5% | 0.0% |
| ROIC | 8.3% | 7.1% |
| Piotroski F | — | 8/9 |
| 1y total return | -15.0% | +0.8% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABT vs MDT
| Metric | ABT | MDT |
|---|---|---|
| End value | $33.2K | $14.5K |
| Total return | +231.6% | +45.4% |
| CAGR | +12.3% | +3.7% |
| Volatility | 23.9% | 23.2% |
| Sharpe | 0.44 | 0.10 |
| Sortino | 0.63 | 0.15 |
| Max drawdown | -39.6% | -45.3% |
Based on 2600 common trading days, 2016-04-28 → 2026-08-31 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)